PARTNERING

Partnering Overview

Targeting unique disease-specific peptide HLA complexes is an essential input for filling immunotherapeutic drug discovery pipelines. Pure MHC’s business development plan makes it easy to partner with mutually favorable terms and creative flexibility to meet your specific corporate needs.  

With Pure MHC’s available suite of research tools, an expansive range of services are available to assist collaborators in answering research and development questions related to epitope validation, development, and therapeutic exploitation of their existing targets.

Partnering Opportunities

Pure MHC is currently seeking partnerships to:

 

Develop therapeutics to novel peptide targets in multiple internal discovery projects. Current target discovery projects in oncology include:

  • Non-small cell lung cancer (NSCLC)
  • Acute myeloid leukemia (AML)
  • Ovarian cancer
  • Colorectal Cancer (CRC)

Current target discovery projects in autoimmunity include:

  • Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)

Collaborate on novel target discovery programs for other oncology indications, infectious diseases, and autoimmune disorders with partners active in specific indications in those fields

Apply its extensive HLA expertise and proprietary tools to:

  • Validate partner epitopes
  • Identify immunogenetic epitopes in gene therapy viral vectors or novel therapeutic proteins delivered as proteins or as part of gene therapy
  • Assist with other related research collaborations

Collaboration Opportunities

Pure MHC’s available suite of research tools allows for an expansive range of services to assist collaborators in answering research and development questions related to epitope validation, development, and therapeutic exploitation of their existing targets.

Unique IP Positioning for Collaborative Partners

Pure MHC holds intellectual property rights on the manufacture of soluble HLA proteins used in a proprietary method of immunogenic epitope discovery and validation. Our business model is focused on the discovery and development of these epitope targets for use by our collaborators in their immunotherapeutic modalities of choice. Such modalities might include TCRs, CAR-Ts, antibody drug conjugates and bispecific antibodies, or T cell eliciting vaccines. The synergistic combination of Pure MHC’s targets in the context of our collaborators’ immunotherapeutic modality provides the opportunity for strong intellectual property protection without starting the patent clock prematurely and using up valuable patent life.

Collaborate with Pure MHC to achieve your corporate and scientific goals.